Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic…

Read More

Whole Blood: The Next Frontier for EMS

For decades, EMS has relied on blood component therapy, which was favored for its longer shelf life, efficiency, and lower risk of transfusion reactions. However, emerging data suggests that whole blood transfusion in the field could significantly improve survival rates, particularly in rural and remote areas where longer transport times pose additional risks. The post…

Read More

Little Otter Raises $9.5M for Family Mental Health

Little Otter’s $9.5 million fundraise included participation from Pivotal Ventures, Torch Capital, Springbank, CRV, Next Legacy, G9, Gratitude Railroad and Carrie Walton Penner’s Fiore Ventures. The company has raised more than $36 million to date. The post Little Otter Raises $9.5M for Family Mental Health appeared first on MedCity News.

Read More